The "omics" 鈥� genomics, transcriptomics, metabolomics and proteomics 鈥� are booming in biotech, with more big raises expected in 2023.
Startups
Dealmakers think 2023 could see a significant jump in M&A volume as companies鈥� options for money and exits dwindle.
Despite 2022's pullback in venture capital funding, 10 companies in the U.S. still broke the $1 billion barrier in individual raises.
After two years of pandemic-fueled valuations, public market climbs and billions in venture funding, bloated tech companies big and small are now...
For 2023, we鈥檙e predicting that startup investors will be looking for novelty in the companies they back. Out with the me-too business plans.
Venture firms have continued to raise record funds in 2022, even as startups received far less money. So what will happen with all that dry powder in...
With layoffs, massive funding pullbacks and an overall sense of doom clouding the economy, we naturally saw attention drawn to our coverage of those...
This year hasn鈥檛 exactly been a blockbuster for the IPO markets. Venture funding has tanked and fewer startups have dared to step into the public...
Now that the end of the year is fast approaching, let鈥檚 look at the five most interesting rounds of the year 鈥� at least in our eyes.
For startups in times like these, Series A is a good place to be. However, given the dropoff after Series A, startups might get stuck unless Series B...
With the world鈥檚 eyes on Argentina, it鈥檚 an opportune time to look at a space that gets way less attention than soccer: the Argentine startup scene.
![Illustration of a guy watering plants with a blocked hose - Global [Dom Guzman]](/wp-content/uploads/quarterly-global-3-300x168.jpg)
67.1K Followers